EDESA BIOTECH, INC. Cost of Revenue
EDESA BIOTECH, INC. (EDSA) reported Cost of Revenue of $0 for the 12-month period ending 2021-09-30, per its 10-K filed 2021-12-28.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2021-12-28
- EDESA BIOTECH, INC. cost of revenue for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- EDESA BIOTECH, INC. cost of revenue for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- EDESA BIOTECH, INC. cost of revenue for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- EDESA BIOTECH, INC. cost of revenue for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- EDESA BIOTECH, INC. cost of revenue for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- EDESA BIOTECH, INC. cost of revenue for fiscal 2020 was $17.60K.
- EDESA BIOTECH, INC. cost of revenue for fiscal 2018 was $0.00.
| Period end | Cost of Revenue 1 month | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | $0.00 derived: sum of 2 quarters · filed 2021-12-28 | $0.00 derived: sum of 3 quarters · filed 2021-12-28 | $0.00 10-K · filed 2021-12-28 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 derived: sum of 2 quarters · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | $2.31K derived: sum of 4 quarters · filed 2021-12-28 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-14 | $0.00 10-Q · filed 2021-05-14 | $2.31K derived: sum of 3 quarters · filed 2021-12-28 | $3.79K derived: sum of 4 quarters · filed 2021-12-28 | |
| 2020-12-31 | $0.00 10-Q · filed 2021-02-16 | $2.31K derived: sum of 2 quarters · filed 2021-12-28 | $3.79K derived: sum of 3 quarters · filed 2021-12-28 | $13.82K derived: sum of 4 quarters · filed 2021-12-28 | |
| 2020-09-30 | $2.31K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | $3.79K derived: sum of 2 quarters · filed 2021-12-28 | $13.82K derived: sum of 3 quarters · filed 2021-12-28 | $17.60K 10-K · filed 2021-12-28 | |
| 2020-06-30 | $1.47K 10-Q · filed 2021-08-13 | $11.51K derived: sum of 2 quarters · filed 2021-08-13 | $15.29K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $10.04K 10-Q · filed 2021-05-14 | $13.81K 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $3.78K 10-Q · filed 2021-02-16 | ||||
| 2019-09-30 | $101.29K 10-K · filed 2020-12-07 | ||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 derived: sum of 2 quarters · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $0.00 10-Q · filed 2020-02-13 | $0.00 10-KT · filed 2019-12-12 | |||
| 2013-09-30 | $34.93K 10-Q · filed 2015-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |